A5020923289- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Phagocytosis and Immune Regulation
- Cancer Research and Treatments
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Immune cells in cancer
- Virus-based gene therapy research
- Genomics, phytochemicals, and oxidative stress
- T-cell and B-cell Immunology
- Metabolism, Diabetes, and Cancer
- Ubiquitin and proteasome pathways
- Nanoparticle-Based Drug Delivery
- DNA Repair Mechanisms
- Immune Cell Function and Interaction
- Immune Response and Inflammation
- Genetics, Aging, and Longevity in Model Organisms
Icosagen (Estonia)
2023-2025
Ludwig-Maximilians-Universität München
2019-2021
University of Tartu
2018
Background: ADORA2A (A2AR), is an adenosine receptor that suppresses immune cell toxicity through sensing extracellular adenosine. A2AR belongs to a group of seven-transmembrane proteins called G protein-coupled receptors (GPCRs) which act as detectors various signals from outside the cell. We aim reduce immunosuppressive properties in tumor microenvironment (TME) by targeting with monoclonal antibodies (mAbs). mAbs are attractive modality therapeutically target complex multi-pass membrane...
Abstract Chimeric antigen receptor (CAR) T cell therapies have achieved remarkable efficacy in treating B malignancies but shown limited clinical success patients with solid tumors. A key challenge advancing these lies the identification and targeting of highly tumor-specific antigens to ensure both safety efficacy. In this study, we employed HybriFree B-cell cloning technology phage display discover antibodies Claudin-6 (CLDN6), an oncofetal protein selectively expressed subsets ovarian,...
Abstract Background: Cancer cells often exhibit upregulated glucose metabolism to support their abnormal growth and division. Targeting the cancer-specific transporter GLUT-1 offers a promising strategy limit uptake disrupt tumor metabolism. Unlike small molecule inhibitors, monoclonal antibodies provide unique opportunity selectively target complex multi-pass membrane transporters. This study presents development of highly specific that recognize glycovariants, effectively blocking function...
Abstract Background: Claudin 6 (CLDN6), a tight junction protein, is an oncofetal antigen with limited expression in adult tissues but aberrantly overexpressed several cancers, including ovarian, testicular, and gastric tumors. Its tumor-specific critical role maintaining cell adhesion make CLDN6 compelling target for cancer therapy. Recent studies have linked to tumor progression, metastasis, chemoresistance, highlighting its potential as both biomarker therapeutic precision oncology. This...
Abstract Coordination of DNA replication and cellular redox homeostasis mechanisms is essential for the sustained genome stability due to sensitivity replicating oxidation. However, substantial gaps remain in our knowledge underlying molecular pathways. In this study, we characterise interaction Keap1, a central antioxidant response regulator Metazoa, with replicative helicase subunit protein MCM3. Our analysis suggests that structural determinants Keap1 its critical downstream target - Nrf2...
Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 "don't eat me signal" is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signal regulatory protein alpha (SIRPα). Activation of macrophages blocking has been successful, but the ubiquitous expression healthy poses potential limitations for such therapies. In contrast, CD123 a well-known LSC-specific surface marker utilized as therapeutic...
Conventional dendritic cell (DC) vaccine strategies, in which DCs are loaded with antigens ex vivo, suffer biological issues such as impaired DC migration capacity and laborious GMP production procedures. In a promising alternative, targeted to DC-associated endocytic receptors vivo antibody–antigen conjugates co-administered toll-like receptor (TLR) agonists adjuvants. To combine the potential advantages of vaccination those conjugated TLR agonists, we generated multifunctional antibody...
Abstract Background: Upregulated glucose metabolism is one of the strategies cancer cells use to fuel their abnormal cell growth and division. Targeting cancer-specific transporter GLUT-1 a promising approach restrict uptake challenge metabolic needs tumor cells. Antibodies, as opposed small molecule inhibitors, are an attractive modality therapeutically target complex muti-pass membrane transporters. Here we report development antibodies that very specifically block function only GLUT-1....
<h3>Background</h3> ADORA2A, is an adenosine receptor that suppresses immune cell toxicity through sensing extracellular adenosine. ADORA2A belongs to a group of seven-transmembrane proteins called G protein-coupled receptors (GPCRs) which act as detectors various signals from outside the cell. We aim reduce immunosuppressive properties by targeting with monoclonal antibodies (mAbs) enhance potency established immunotherapies. mAbs are attractive modality therapeutically target complex...
Abstract Background: Alterations in tumor cell metabolism are one of the central processes guiding cancer progression. The increased glucose dependence cells, also known as Warburg effect, opens possibility to therapeutically target glycolytic pathway and challenge metabolic needs cells. We generated 24 monoclonal antibodies targeting main transporter on cells - SLC2A1 (GLUT1). evaluated ability affect fitness alone combination with OXPHOS inhibitors find clinically applicable therapeutics...
<h3>Background</h3> Despite advances in the development of novel strategies against acute myeloid leukemia (AML), treatment options are limited and most patients relapse. Relapse occurs due to persistence chemotherapy-resistant leukemic stem cells (LSCs), which re-initiate outgrowth disease, highlighting need targeting LSCs improve patient survival. characterized by expression interleukin-3 receptor α, also known as CD123. CD123 is expressed on AML blasts LSCs, shows a moderate normal...